


PHARMACEUTICAL 2017

Immune Therapeutics Inc. Rank 304 of 313





PHARMACEUTICAL 2017

Immune Therapeutics Inc. Rank 304 of 313

The relative strengths and weaknesses of Immune Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immune Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 2,204% points. The greatest weakness of Immune Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 1,278% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,951%, being 1,535% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	74
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,201
Liabilities, Non-Current	0
Other Assets	0.20
Other Compr. Net Income	0
Other Expenses	9,945
Other Liabilities	0
Other Net Income	-5,547
Property and Equipment	1.9
Research and Development	444
Revenues	3.5
Selling, General and Administrative Expense	3,887

Output Variable	Value in 1000 USD
Assets	76
Liabilities	9,201
Expenses	14,275
Stockholders Equity	-9,124
Net Income	-19,819
Comprehensive Net Income	-19,819
Economic Capital Ratio	-1,951%